会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS
    • CC-1065和DUOCARMYCINS的肝脏类似物的组合物及其使用方法
    • WO02030894A2
    • 2002-04-18
    • PCT/US2001/029160
    • 2001-09-19
    • C07D235/18A61K31/167A61K31/4025A61K31/404A61K31/4184A61K31/496A61P35/00C07C215/76C07C231/10C07C233/24C07C235/38C07C271/28C07C271/30C07D207/34C07D207/40C07D207/416C07D209/42C07D213/64C07D213/69C07D235/24C07D405/12C07D405/14C07D209/00
    • C07D207/416C07C215/76C07C235/38C07C271/28C07C271/30C07D209/42C07D213/64C07D213/69C07D235/24C07D405/12Y02P20/55
    • The present invention relates to novel achiral seco -analogues of the DNA minor groove and sequence-selective alkylating agents (+)-CC1065 and the duocarmycins, depicted as general class I, II, III, IV and V wherein X is a good leaving group, such as a chloride, a bromide, an iodide, a mesylate, a tosylate, an acetate, a quaternary ammonium moiety, a mercaptan, an alkylsulfoxyl, or an alkylsulfonyl group, preferably either a chloride, a bromide, or an iodide group. R1 is suitable minor groove binding agent to enhance the interactions of the achiral seco-cyclopropaneindole (CI) or an achiral seco -duocarmycin with specific sequences of DNA. Examples of the DNA binders are given in Table 4. The preferred DNA binders are groups A, C, D, E, F, G, H and I. R1 can also include the following: t-butoxy, benzyloxy, 9-flurenylmethyloxy or other common protecting groups for amines wherein X is a good leaving group, such as a chloride, a bromide, an iodide, a mesylate, a tosylate, an acetate, a quaternary ammonium moiety, a mercaptan, an alkylsulfoxyl, or an alkylsulfonyl group, preferably either a chloride, a bromide, or an iodide group. R1 is a suitable minor groove binding agent to enhance the interactions of the covalently reactive achiral seco -pharmacophore with specific sequences of DNA. Examples of the DNA binders are given in Table 4. The preferred DNA binders are groups A, C, D, E, F, G, H, I, J, K and L. R2 and R3 can be hydrogen or short chain alkyl (C1-C5) groups, preferably both being hydrogen atoms. The alkyl groups may be straight chain or branched and include such groups as ethyl, propyl, butyl, pentyl and hexyl. R4 et R5 can be hydrogen atoms, short alkyl groups, trifluoromethyl moieties, and alkyloxycarbonyl groups. The preferred R4 and R5 groups are methoxycarbonyl and trifluoromethyl. R can be either a benzyl, a benzyloxycarbonyl, a hydrogen atom, a 4-nitrobenzyloxycarbonyl, or a N'-methylpiperazinyl-N-carbonyl group wherein X is a good leaving group, R1 is a minor groove binding agent, such as the binding units of adozelesin and duocarmycins, netropsin and bisbenzimide. R2 and R3 can be hydrogen or short-chain alkyl (C1-C5) groups. R4 and R5 can be hydrogen atoms, short alkyl groups, trifluoromethyl moieties, and alkyloxycarbonyl groups. R can be either a benzyl, a benzyloxycarbonyl, a hydrogen atom, a 4-nitrobenzyloxycarbonyl, or a N'-methylpiperazinyl-N-carbonyl group. The present invention is further directed to pharmaceutical compositions thereof, and as a method for treatment of cancer using the subject compounds.
    • 本发明涉及DNA次要槽的新型非手性分子和序列选择性烷化剂(+)-C CC1065和二卡马霉素,其被描述为一般类别I,II,III,IV和V 其中X为良好的离去基团,例如氯化物,溴化物,碘化物,甲磺酸酯,甲苯磺酸酯,乙酸酯,季铵部分,硫醇,烷基亚砜基或烷基磺酰基,优选氯, 溴化物或碘化物基团。 R1是适合的小沟结合剂,以增强非手性仲环丙烷吲哚(CI)或非手性分解 - 多克霉素与特定DNA序列的相互作用。 DNA粘合剂的实例在表4中给出。优选的DNA结合剂是A,C,D,E,F,G,H和I.组合.R1还可包括以下:叔丁氧基,苄氧基,9-氟脲基甲氧基或 其它常用的胺保护基,其中X是良好的离去基团,例如氯化物,溴化物,碘化物,甲磺酸酯,甲苯磺酸酯,乙酸酯,季铵部分,硫醇,烷基亚砜基或烷基磺酰基, 优选氯化物,溴化物或碘化物基团。 R1是一种合适的小沟结合剂,用于增强共价反应性非手性分子 - 药物基团与特定DNA序列的相互作用。 DNA粘合剂的实例在表4中给出。优选的DNA粘合剂是A,C,D,E,F,G,H,I,J,K和L.组合.R 2和R 3可以是氢或短链烷基 C1-C5)基团,优选两个都是氢原子。 烷基可以是直链或支链的,包括乙基,丙基,丁基,戊基和己基等基团。 R4和R5可以是氢原子,短烷基,三氟甲基部分和烷氧基羰基。 优选的R4和R5基团是甲氧基羰基和三氟甲基。 R可以是苄基,苄氧基羰基,氢原子,4-硝基苄氧羰基或N'-甲基哌嗪基-N-羰基,其中X是好的离去基团,R 1是小沟结合剂,例如结合 青霉素和杜卡霉素单位,肌钙蛋白和双苯甲酰亚胺。 R2和R3可以是氢或短链烷基(C1-C5)基团。 R4和R5可以是氢原子,短烷基,三氟甲基部分和烷氧基羰基。 R可以是苄基,苄氧基羰基,氢原子,4-硝基苄氧羰基或N'-甲基哌嗪基-N-羰基。 本发明还涉及其药物组合物,以及作为使用本发明化合物治疗癌症的方法。